Development of guidelines for the management of patients with open fractures: The potential cost-savings of international collaboration

Verheul, Elfi; Berner, Juan Enrique; Oflazoglu, Kamilcan; Troisi, Luigi; Arnež, Zoran Marij; Ortega-Briones, Alina; Nanchahal, Jagdeep; Rakhorst, Hinne

doi:10.1016/j.bjps.2021.08.047

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PBMs have been studied and considered effective in controlling pain, edema, and tissue repair A clinical trial with 68 participants with tibial fracture compared the use of laser in the wavelength of 830 nanometers and 26J/cm2 with a placebo. It demonstrated that the PBM group represented a faster resolution of pain and ambulation cases than the control [25].…”

Section: Plos Onementioning

confidence: 94%

Cost analysis of photobiomodulation in tibia fracture in the Brazilian public health system

Jana Neto,

Martimbianco,

de Medeiros

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Managing tibial fractures requires substantial health resources, which costs the health system. This study aimed to describe the costs of photobiomodulation (PBM) with LEDs in the healing process of soft tissue lesions associated with tibial fracture compared to a placebo. Economic analysis was performed based on a randomized controlled clinical trial, with a simulation of the cost-effectiveness and incremental cost model. Adults (n = 27) hospitalized with tibia fracture awaiting definitive surgery were randomized into two distinct groups: the PBM Group (n = 13) and the Control Group with simulated phototherapy (n = 14). To simulate the cost-effectiveness and incremental cost model, the outcome was the evolution of wound resolution by the BATES-JENSEN scale and time of wound resolution in days. The total cost of treatment for the Control group was R$21,164.56, and a difference of R$7,527.10 more was observed when compared to the treatment of the PBM group. The proposed intervention did not present incremental cost since the difference in the costs to reduce measures between the groups was smaller for the PBM group. When analyzing the ICER (Incremental cost-effectiveness ratio), it would be possible to save R$3,500.98 with PBM and decrease by 2.15 points in the daily average on the BATES-JENSEN scale. It is concluded, therefore, that PBM can be a supportive therapy of clinical and economic interest in a hospital setting.

show abstract

Section: Plos Onementioning

confidence: 94%